

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claim 1 (canceled)

Claim 2 (previously presented): The method according to claim 10, wherein the pulmonary hypertension is selected from primary pulmonary hypertension or secondary pulmonary hypertension.

Claim 3 (canceled)

Claim 4 (previously presented): The method according to claim 3 wherein the daily dose is administered for a period exceeding three months.

Claim 5 (previously presented): The method according to claim 10 wherein the pulmonary hypertension is not caused or accompanied by pulmonary fibrosis.

Claim 6 (canceled)


Claim 7 (previously presented): The method according to claim 6 wherein N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine is in the form of the monomethanesulfonate salt.

Claim 8 (canceled)

Claim 9 (canceled)

Claim 10 (currently amended): A method of treating humans suffering from pulmonary hypertension which comprises administering to a said human in need of such treatment a dose, effective against pulmonary hypertension, of N-{5-[4-(4-methyl-piperazino-methyl)-

benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine



(I)

or a pharmaceutically acceptable salt thereof, wherein a daily dose of 100 to 1000 mg of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or a pharmaceutically acceptable salt thereof is administered to an adult human.